This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354–365.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209–2221.
Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR . Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. Br J Haematol 2014; 164: 245–250.
Lazarevic V, Horstedt AS, Johansson B, Antunovic P, Billstrom R, Derolf A et al. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. Eur J Haematol 2015; 94: 419–423.
Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013; 27: 75–81.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145: 318–332.
Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360–3368.
Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol 2011; 155: 366–376.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.
Shaffer LG, McGowan-Jordan J, Schmid M. An International System for Human Cytogenetic Nomenclature (ISCN). S Karger: Basel, Switzerland, 2013..
Swansbury GJ . The proportion of clonal divisions varies in different hematologic malignancies. Cancer Genet Cytogenet 1998; 104: 139–145.
Moorman AV, Roman E, Kane EV, Dovey GJ, Cartwright RA, Morgan GJ . Karyotype and age in acute myeloid leukaemia: Are they linked? Cancer Genet Cytogenet 2001; 126: 155–161.
Cox MC, Panetta P, Venditti A, Del Poeta G, Maurillo L, Tamburini A et al. Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/mll+ translocation in leukaemia. Br J Haematol 2003; 121: 953–955.
Hawkins JM, Secker-Walker LM . Evaluation of cytogenetic samples and pertinent technical variables in adult acute lymphocytic leukemia. Cancer Genet Cytogenet 1991; 52: 79–84.
Acknowledgements
We thank all the patients, clinicians and staff who participated in the Medical Research Council/National Cancer Research Institute AML trials. We are also grateful to the member laboratories of the UK Cancer Cytogenetic Group for providing cytogenetic data and the members of the NCRI AML Working Group for their support. This work was supported by Bloodwise (formerly Leukaemia and Lymphoma Research, UK).
Author contributions
LC, AVM and RKH designed the study; LC, IA, RKH, DM, CJH and AVM analysed and interpreted the data. DG and RKH provided clinical and follow-up data; AKB was the chief investigator on all trials. CJH and AVM provided financial and administrative support. AVM wrote the manuscript with input and approval from all the other authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chilton, L., Harrison, C., Ashworth, I. et al. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 31, 1234–1237 (2017). https://doi.org/10.1038/leu.2017.37
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.37